Objective: The aim of this study is to observe the effect of Androgen Deprivation Therapy (ADT) on patients with advanced stage of prostate cancer on the lipid profile and blood glucose level. Material & Methods: This is a descriptive cross-sectional study and include the prostate cancer patients which were admitted to Urology Policlinic in Haji Adam Malik General Hospital, Medan from June 2014 – June 2015 and also received ADT. Results: From June 2014 – June 2015, a total of 25 prostate cancer patients receiving ADT was included in this study with an average age of 67.08 ± 7.48 years old. The median prostate specific antigen (PSA) level of this group of patients is 19.6 ng/mL and the lowest and highest value of 3.4 and 278 ng/mL respectively. ADT administration is found to cause a significant elevation of 2-hour postprandial blood glucose (121.12 ± 21 mg/mL vs 134.64 ± 33.35 mg/mL, p-value=0.011) and Glycosylated hemoglobin (5 ± 0.5% vs 5.5 ± 0.79%, p-value=0.000) (HbA1c) after 6 months of therapy. Additionally, ADT administration within 3 and 6 months of duration had also significantly increased triglyceride (TG) level when compared to before treatment (104.4 ± 38.67 vs 131.2 ± 32.27 vs 127 ± 33.43 respectively, p-value=0.005). Conclusion: ADT treatment in prostate cancer patients increase triglyceride levels after 3 and 6 months of treatment followed by 2-hour postprandial blood glucose and HbA1C levels after 6 months of the treatment.
Prostate cancer, androgen deprivation therapy, Haji Adam Malik General Hospital
Nelson JB. Hormone therapy for prostate cancer. In Campbell Walsh Urology; 2012. p. 2920–53.
Mohamedali HZ. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Canadian Urological Association; 2011. p. 23–32.
Basaria MB. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impotence Res; 2006. p. 494–8.
Saglam HS. Fasting blood glucose and lipid profile alterations following twelve month androgen deprivation therapy in men with prostate cancer. Scientific World Journal; 2012. p. 1–4.
Poppel HV, tombal B. Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Management and Research; 2011. p. 49–55.
Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. J Androl; 2008. p. 534–9.
Basaria. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Wiley Interscience; 2005.
Roayaei M, Ghasemi S. Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer. J Res Med Sci; 2013. p. 580–2.
Nishiyama T. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab; 2005. p. 657–60.
Hamilton EJ. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol; 2011. p. 377–83.
Morote J. Metabolic syndrome and its components in prostate cancer patients under androgen deprivation therapy. J Urol; 2015.